DK0576439T3 - Monoklonalt antistof mod LPS-kerne - Google Patents

Monoklonalt antistof mod LPS-kerne

Info

Publication number: DK0576439T3
Authority: DK; Denmark
Prior art keywords: thr; leu; tyr; arg; ser
Prior art date: 1991-03-13

Application number

DK92904901T

Other languages

Danish (da)

English (en)

Inventor

Hermann Gram

Padova Franco Di

George Robin Barclay

Ian Raymond Poxton

Original Assignee

Common Services Agency

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-13

Filing date

1992-02-22

Publication date

1999-11-01

1992-02-22 Application filed by Common Services Agency filed Critical Common Services Agency

1999-11-01 Application granted granted Critical

1999-11-01 Publication of DK0576439T3 publication Critical patent/DK0576439T3/da

Links

AAXCQFOXUJMCCW-PETQGJDISA-N LPS core Chemical compound O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@@H](OC3[C@H]([C@@H](OC4[C@H]([C@@H](OC5[C@@H]([C@@H](O[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)OC6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)O)O5)O)[C@H](O)[C@@H]([C@@H](O)COC5[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O5)O)O4)O)[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)O3)O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](O[C@]4(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C4)[C@@H](O)CO)C(O)=O)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O AAXCQFOXUJMCCW-PETQGJDISA-N 0.000 title 1
241001529936 Murinae Species 0.000 abstract 3
150000001413 amino acids Chemical group 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 abstract 1
IICZCLFBILYRCU-WHFBIAKZSA-N Asn-Gly-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IICZCLFBILYRCU-WHFBIAKZSA-N 0.000 abstract 1
GOKCTAJWRPSCHP-VHWLVUOQSA-N Asn-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)N)N GOKCTAJWRPSCHP-VHWLVUOQSA-N 0.000 abstract 1
MYCSPQIARXTUTP-SRVKXCTJSA-N Asn-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N MYCSPQIARXTUTP-SRVKXCTJSA-N 0.000 abstract 1
ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 abstract 1
ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 abstract 1
241000894006 Bacteria Species 0.000 abstract 1
208000037487 Endotoxemia Diseases 0.000 abstract 1
WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 abstract 1
IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 abstract 1
GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 abstract 1
GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 abstract 1
QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 abstract 1
DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 abstract 1
AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 abstract 1
UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 abstract 1
241000699670 Mus sp. Species 0.000 abstract 1
ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 abstract 1
LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 abstract 1
FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 abstract 1
VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
230000004927 fusion Effects 0.000 abstract 1
210000004408 hybridoma Anatomy 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
108010080629 tryptophan-leucine Proteins 0.000 abstract 1
108010071635 tyrosyl-prolyl-arginine Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/50—Lipopolysaccharides; LPS

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Immunology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK92904901T 1991-03-13 1992-02-22 Monoklonalt antistof mod LPS-kerne DK0576439T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919105292A GB9105292D0 (en)	1991-03-13	1991-03-13	Improvements in or relating to organic compounds
PCT/EP1992/000380 WO1992016624A1 (fr)	1991-03-13	1992-02-22	Anticorps monoclonal dresse contre le noyau de lipopolysaccharide

Publications (1)

Publication Number	Publication Date
DK0576439T3 true DK0576439T3 (da)	1999-11-01

Family

ID=10691487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92904901T DK0576439T3 (da)	1991-03-13	1992-02-22	Monoklonalt antistof mod LPS-kerne

Country Status (10)

Country	Link
EP (1)	EP0576439B1 (fr)
JP (1)	JP3328277B2 (fr)
AT (1)	ATE179753T1 (fr)
AU (1)	AU1261192A (fr)
CA (1)	CA2105979C (fr)
DE (1)	DE69229110T2 (fr)
DK (1)	DK0576439T3 (fr)
ES (1)	ES2131526T3 (fr)
GB (1)	GB9105292D0 (fr)
WO (1)	WO1992016624A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU585200B2 (en) *	1983-05-06	1989-06-15	Velos Group	Monoclonal antibodies reactive with endotoxin core
AU684041B2 (en) *	1992-02-19	1997-12-04	Schering Corporation	Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US6749831B1 (en)	1997-05-16	2004-06-15	Medical Defense Technology, Llc	Vaccine against lipopolysaccharide core
US7772372B2 (en)	2002-07-04	2010-08-10	Patrys Limited	Neoplasm specific antibodies and uses thereof
DE10311248A1 (de)	2003-03-14	2004-09-30	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper
DE10353175A1 (de)	2003-11-14	2005-06-16	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (fr)	2003-11-14	2005-05-18	Heinz Vollmers	Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
US10117930B2 (en) *	2009-04-27	2018-11-06	Immuron Limited	Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder
ES2628032T3 (es)	2010-08-17	2017-08-01	Immuron Limited	Preparación de inmunoglobulina enriquecida con anti-LPS para su uso en el tratamiento y/o la profilaxis de un trastorno patológico
DE102011006809A1 (de)	2011-04-05	2012-10-11	Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg	Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
DE102011006781A1 (de) *	2011-04-05	2012-10-11	Mat-Malta Advanced Technologies Limited	Antikörperprodukt, umfassend n spezifische Antikörper
AU2016353073A1 (en)	2015-11-10	2018-06-07	Visterra, Inc.	Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
CA3049449A1 (fr)	2017-01-18	2018-07-26	Visterra, Inc.	Conjugues molecule d'anticorps-medicament et leurs utilisations
CN116710146A (zh)	2020-04-03	2023-09-05	威特拉公司	抗体分子-药物偶联物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU585200B2 (en) *	1983-05-06	1989-06-15	Velos Group	Monoclonal antibodies reactive with endotoxin core
EP0183876A1 (fr) *	1984-11-27	1986-06-11	The Board Of Trustees Of The Leland Stanford Junior University	Anticorps monoclonaux pour le noyau d'endotoxines et leur application
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
FR2606421B1 (fr) *	1986-11-12	1990-01-26	Roussel Uclaf	Anticorps monoclonaux antigram (-) procede de preparation et applications
GB2218703B (en) *	1988-05-10	1992-10-28	Sumitomo Chemical Co	Human monoclonal antibody to p.aeruginosa: its production and use
WO1990003186A1 (fr) *	1988-09-19	1990-04-05	Cetus Corporation	Endotoxine bacterienne gram negative bloquant des anticorps monoclonaux

1991
- 1991-03-13 GB GB919105292A patent/GB9105292D0/en active Pending
1992
- 1992-02-22 EP EP92904901A patent/EP0576439B1/fr not_active Expired - Lifetime
- 1992-02-22 AT AT92904901T patent/ATE179753T1/de not_active IP Right Cessation
- 1992-02-22 JP JP50491892A patent/JP3328277B2/ja not_active Expired - Fee Related
- 1992-02-22 DE DE69229110T patent/DE69229110T2/de not_active Expired - Fee Related
- 1992-02-22 CA CA002105979A patent/CA2105979C/fr not_active Expired - Fee Related
- 1992-02-22 AU AU12611/92A patent/AU1261192A/en not_active Abandoned
- 1992-02-22 ES ES92904901T patent/ES2131526T3/es not_active Expired - Lifetime
- 1992-02-22 WO PCT/EP1992/000380 patent/WO1992016624A1/fr active IP Right Grant
- 1992-02-22 DK DK92904901T patent/DK0576439T3/da active

Also Published As

Publication number	Publication date
AU1261192A (en)	1992-10-21
JP3328277B2 (ja)	2002-09-24
JPH06505867A (ja)	1994-07-07
ATE179753T1 (de)	1999-05-15
EP0576439B1 (fr)	1999-05-06
GB9105292D0 (en)	1991-04-24
ES2131526T3 (es)	1999-08-01
CA2105979A1 (fr)	1992-09-14
DE69229110T2 (de)	1999-11-25
EP0576439A1 (fr)	1994-01-05
DE69229110D1 (de)	1999-06-10
WO1992016624A1 (fr)	1992-10-01
CA2105979C (fr)	2003-05-13

Publication	Publication Date	Title
DK0576439T3 (da)	1999-11-01	Monoklonalt antistof mod LPS-kerne
US6342587B1 (en)	2002-01-29	A33 antigen specific immunoglobulin products and uses thereof
RU2017137010A (ru)	2019-04-23	Анти-сеасам6 антитела и их применения
CA2012993A1 (fr)	1990-09-24	Anticorps monoclonaux contre les antigenes associes a des tumeurs, leur preparation et leur utilisation
JP6400480B2 (ja)	2018-10-03	ペプチドグリカン認識タンパク質１に結合する抗体
KR970707160A (ko)	1997-12-01	인체 인터루킨 5 수용체 알파-사슬에 대한 항체 (antibody against alpha-chain of human interleukin 5 receptor)
US20200347130A1 (en)	2020-11-05	CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
MY145703A (en)	2012-03-30	Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
RU96115107A (ru)	1999-05-20	"очеловеченные" антитела и их использование
CY1113296T1 (el)	2016-04-13	Υβριδικο ανθρωπινο/τρωκτικου ιgg αντισωμα προς cd3 και μεθοδοι κατασκευης αυτου
RU2003100512A (ru)	2004-07-10	Антитела к человеческому мср-1
RU2013114368A (ru)	2014-10-20	Пептид или пептидный комплекс, связывающийся с альфа-интегрином, способы его получения и применения указанного вещества
US20250011455A1 (en)	2025-01-09	ANTI-CD39 Antibody, Preparation Method Therefor And Use Thereof
DE3485432D1 (de)	1992-02-20	Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
JP2020521504A (ja)	2020-07-27	抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
CN107522783A (zh)	2017-12-29	一种抗白介素17a 的抗体、其制备方法和应用
CA2525657A1 (fr)	2004-11-25	Anticorps monoclonal humain specifique de lipopolysaccharides (lps) du serotype iats o6 de pseudomonas aeruginosa
CN110461874B (zh)	2022-04-12	抗gitr抗体、其抗原结合片段及其医药用途
WO2019200255A1 (fr)	2019-10-17	Anticorps monoclonal humain spécifique de la capsule de mycobacterium tuberculosis à haute affinité
US20230365679A1 (en)	2023-11-16	Anti-cd22 antibody molecule or antigen-binding fragment and use thereof
Muneta et al.	2000	Production of monoclonal antibodies to porcine interleukin-18 and their use for immunoaffinity purification of recombinant porcine interleukin-18
CN113661176B (zh)	2025-02-18	用于预防和治疗单纯疱疹病毒感染的单克隆抗体
KR890016165A (ko)	1989-11-28	수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
CN105061596B (zh)	2019-01-29	人b淋巴细胞刺激因子的单克隆抗体及其应用
CN114957468A (zh)	2022-08-30	一种抗Siglec15抗体及其用途